Repligen to Present at 35th Annual J.P. Morgan Healthcare Conference
January 04 2017 - 6:30AM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced that it
will present at the 35th Annual J.P. Morgan Healthcare conference
being held January 9-12 at the Westin St. Francis in San Francisco.
Tony J. Hunt, President and Chief Executive Officer, will
make a formal presentation on Thursday, January 12, at 11:00 a.m.
PST.
A live webcast of the presentation will be accessible through
the Investor Events section of the Company’s website, and will be
available for replay for a limited period of time following the
conference event.
About Repligen
CorporationRepligen Corporation (NASDAQ:RGEN) is a
bioprocessing company focused on the development, manufacture and
commercialization of highly innovative products used to improve the
process of manufacturing biologic drugs. Our bioprocessing products
are sold to major life sciences companies, biopharmaceutical
development companies and contract manufacturing organizations
worldwide. We are the leading manufacturer of Protein A affinity
ligands, a critical component of Protein A resins that are used to
separate and purify monoclonal antibody-based therapeutics. In
upstream processes, our XCell™ ATF systems and growth factors are
used to accelerate and increase productivity during the cell
culture stage of biologic drug manufacturing. In downstream
processes, we developed and market our innovative line of OPUS®
chromatography columns that we deliver pre-packed with our
customers’ choice of resin for their bench-scale through clinical
production-scale purification needs. With the acquisition of
TangenX, we also manufacture single-use Sius™ TFF cassettes and
hardware, used in downstream protein concentration and filtration
processes. Repligen’s corporate headquarters are in Waltham, MA
(USA) and our manufacturing facilities are located in Waltham, MA,
Shrewsbury, MA, Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Contact:
Sondra S. Newman
Senior Director Investor Relations
Repligen Corporation
(781) 419-1881
snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From May 2023 to May 2024